ReviewProteomes2024
Biomarkers in Ovarian Cancer: Towards Personalized Medicine.
Review in Proteomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Emerging nanotechnologies and their role in early ovarian cancer detection, diagnosis and interventions.Journal of ovarian research · 2025Pooled it
- The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- Immunohistochemical expression of JAK2, STAT3, POLH, UBE2T, and REV7 in serous ovarian carcinoma: clinicopathological associations and co-expression patterns.Journal of molecular histology · 2026Article
- Extracellular matrix polysaccharides and glycoproteins in ovarian cancer: structural-functional macromolecular perspectives and potential exosome-derived biomarkers.Cell communication and signaling : CCS · 2026Review
- A comprehensive review of the emerging role of NRF3 in ovarian cancer tumorigenesis and progression.Journal of ovarian research · 2026Review
- Genetic and Molecular Determinants of Immunotherapy Response in Recurrent Ovarian Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Women with suspected diagnosis of ovarian cancer in Ghana: how much do we know about them?Frontiers in oncology · 2026Article
- Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms.Cancers · 2025Review
- Identification of novel biomarkers for epithelial ovarian cancer through machine learning and explainable artificial intelligence using in silico and in vitro analysis.Scientific reports · 2025Article
- A Review on Biomarker-Enhanced Machine Learning for Early Diagnosis and Outcome Prediction in Ovarian Cancer Management.Cancer medicine · 2025Review
- Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer.NPJ precision oncology · 2025Article
- Article
- Meigs' syndrome with elevated CA-125 and HE-4: a case report and literature review.Frontiers in medicine · 2025Article
- The Role of the Plasminogen Activator Inhibitor 1 (Global medical genetics · 2024Review
- Article
- Article
- Review
- Exploring Radioiodinated Anastrozole and Epirubicin as AKT1-Targeted Radiopharmaceuticals in Breast Cancer: In Silico Analysis and Potential Therapeutic Effect with Functional Nuclear Imagining Implications.Molecules (Basel, Switzerland) · 2024Article
- Activity of NAD(P)H-Oxidoreductases in Ovarian Cancer.Biomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ovarian cancer is one of the deadliest cancers in women. The lack of specific symptoms, especially at the initial stages of disease development, together with the malignancy heterogeneity, lower the life expectancy of patients. Aiming to improve survival rates, diagnostic and prognostic biomarkers are increasingly employed in clinics, providing gynecologists and oncologists with new tools to guide their treatment decisions. Despite the vast number of investigations, there is still an urgent need to discover more ovarian cancer subtype-specific markers which could further improve patient classification. To this end, high-throughput screening technologies, like mass spectrometry, are applied to deepen the tumoral cellular landscape and describe the malignant phenotypes. As for disease treatment, new targeted therapies, such as those based on PARP inhibitors, have shown great efficacy in destroying the tumoral cells. Likewise, drug-nanocarrier systems targeting the tumoral cells have exhibited promising results. In this narrative review, we summarize the latest achievements in the pursuit of biomarkers for ovarian cancer and recent anti-tumoral therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.